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We examined the role of immunoglobulin (Ig)G antibodies in mediating host defense to 
the intracellular parasite, Leishmania. We show that IgG not only fails to provide protection 
against this intracellular pathogen, but it actually contributes to disease progression. The J
 
H
 
 
strain of BALB/c mice, which lack IgG because they have a targeted deletion in the Ig heavy 
chain (J) locus, were more resistant to infection with 
 
Leishmania major
 
 than were normal 
BALB/c mice. However, the passive administration of anti-Leishmania IgG caused J
 
H
 
 mice 
to develop large lesions containing high numbers of parasites. Antibody administration 
correlated with an increase in interleukin (IL) 10 production in lesions, and blocking the 
murine IL-10 receptor prevented antibody-mediated disease exacerbation. In human 
patients with active visceral leishmaniasis, high IgG levels are predictive of disease. Patients 
with ongoing disease had high IgG antibody titers and no delayed-type hypersensitivity 
(DTH) responses to Leishmania antigens. This pattern was reversed upon disease resolution 
after treatment, resulting in a decrease in total IgG, which was accompanied by a 
progressive increase in DTH responsiveness. We conclude that IgG can cause a novel form 
of immune enhancement due to its ability to induce IL-10 production from macrophages.
 
Leishmania are protozoan parasites that reside
predominantly, if not exclusively, in host tissue
macrophages. This organism is a significant hu-
man pathogen, causing a spectrum of diseases
in man (for reviews see references 1, 2). The
disease is transmitted by infected phlebotamine
sandflies, which transfer the flagellated promas-
tigote form to the host. These organisms rapidly
gain entry into phagocytic leukocytes, and
transform into the oval, nonmotile amastigote
form. Amastigotes replicate intracellularly within
macrophage phagolysosomes, and spread the
infection to adjacent macrophages.
The murine model of cutaneous leishma-
niasis caused by 
 
Leishmania major
 
 has served as
a paradigmatic model in which to study cellular
immunity to an intracellular pathogen. In this
model, the development of a Th1 response by
resistant strains of mice led to the production
of IFN-
 
 
 
 and the development of small lesions
with relatively few parasites. However, in the
BALB/c mouse, the inappropriate induction
of a Th2 response led to the development of
larger lesions with high parasitemia. These
mice fail to control the disease and eventually
succumb to infection. This model has done
much to help us understand the events leading
to T cell biasing and immune deviation.
Recently, IL-10 has been identified as an
important mediator of susceptibility in both
murine cutaneous and visceral leishmaniasis
(VL; references 3–5). This cytokine has long
been shown to be elevated in humans suffering
with VL (6). In a recent paper, Murray et al.
demonstrated that macrophage-derived IL-10
can increase susceptibility to 
 
L. major
 
 (7). In
the present work, we examine a potential
mechanism whereby IL-10 is produced by
macrophages during Leishmania infection.
Classically activated macrophages play a
central role in cell-mediated immunity. These
cells produce an array of proinflammatory
cytokines, which have the potential to con-
tribute to autoimmune pathologies when over-
produced (8). We have previously shown that
macrophages activated in the presence of
immune complexes shut off IL-12 biosynthesis
(9) and secrete high levels of IL-10 (10).
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The prediction from these previous in vitro observations was
that immune complexes could adversely influence the devel-
opment of cell-mediated immunity by virtue of this reciprocal
alteration in cytokine production (11). In the present studies,
we examined the role of IgG during infections caused by the
intracellular protozoan parasite 
 
Leishmania
 
 spp. We show that
in both experimental animals infected with 
 
L. major
 
, and in
humans with VL, the presence of IgG immune complexes
correlates with an inability to resolve infections. Thus, these
studies demonstrate that IgG immune complexes can be det-
rimental to a host infected with this intracellular pathogen.
 
RESULTS
IgG promotes lesion progression in mice lacking IgG
 
To determine a role for IgG antibodies in the host immune
response to 
 
Leishmania
 
 spp., we infected normal BALB/c
mice with 
 
L. major
 
 parasites and compared the course of in-
fection to that which occurred in the J
 
H
 
 strain of mice on the
BALB/c background. J
 
H
 
 mice have a targeted deletion of the
immunoglobulin heavy chain J locus and, therefore, make
no antibody. Normal BALB/c mice are susceptible to Leish-
mania infections (12) and developed large lesions, as ex-
pected (Fig. 1, closed circles). The passive administration of
polyclonal anti–
 
L. major
 
 antiserum to wild-type BALB/c
mice had essentially no effect on lesion progression (Fig. 1,
open circles). These mice developed lesions with the same
size and kinetics as mice that received no antisera. Further-
more, the two groups of BALB/c mice had similar numbers
of parasites within their lesions at the conclusion of the ob-
servation period (Fig. 1, inset). However, infections of J
 
H
 
mice with the same number of parasites resulted in a differ-
ent outcome. J
 
H
 
 mice were relatively resistant to disease, de-
veloping modest lesions (Fig. 1, closed triangles) that con-
tained several orders of magnitude fewer parasites (Fig. 1,
inset). In three separate experiments, using a minimum of
four mice per experimental group, the mean lesion size of
infected J
 
H
 
 mice was 1.22 
 
 
 
 0.31 mm at 35 d after infection,
whereas infected BALB/c mice developed lesions that were
5.01 
 
 
 
 0.43 mm. The passive administration of immune se-
rum to J
 
H
 
 mice reversed this resistant phenotype and actually
exacerbated disease, restoring lesion size to that observed in
wild-type BALB/c mice (Fig. 1, open triangles). The num-
ber of parasites in these lesions was comparable to that ob-
served in wild-type BALB/c mice (Fig. 1, inset).
A similar study was performed, except that anti–
 
L. major
 
antiserum was administered to J
 
H
 
 mice after the infection
had progressed for 3 wk. This was done to determine the ki-
netics with which antibody to 
 
L. major
 
 could exacerbate in-
fections (Fig. 2). In these studies, two groups of J
 
H
 
 mice
were infected with 
 
L. major
 
 for 3 wk. One of the groups was
given a single 200-
 
 
 
l i.p. injection of anti–
 
L. major
 
 antise-
rum. Within 1 wk of antiserum administration, footpad le-
sions in this group were already significantly larger than the
controls (Fig. 2). 3 wk after the injection of antiserum, the
lesions had progressed to a point where their size (Fig. 2,
open circles) and the number of parasites within them (Fig. 2,
inset) was comparable to susceptible BALB/c mice. Similar
studies were performed using IgG that was affinity purified
from the immune serum used in Fig. 2. A single i.p. injection
of 600 
 
 
 
g of purified 
 
 
 
–
 
L. major
 
 (
 
 
 
Lm)-IgG into mice at
3 wk after infection caused a similar increase in lesion forma-
tion with similar kinetics as unfractionated immune serum
Figure 1. Serum reconstitution of JH mice. Lesion size of JH mice 
(closed triangles) and BALB/c mice (closed circles) was compared with JH 
mice (open triangles) and BALB/c mice (open circles) given 200  l of anti-
sera to L. major on days 1, 7, and 14. Parasite burdens (inset) in BALB/c 
and JH mice that were infected with (diagonally striped bars) or without 
(black bars)  Lm ( –L. major) antisera were determined on day 35 by lim-
iting dilution assays as described previously (reference 3). Error bars repre-
sent the standard error of the mean of three separate experiments done 
with a minimum of four mice per group.
Figure 2. Serum reconstitution of JH mice 3 wk after infection. 
Lesion size of JH mice (closed circles) were compared with those of JH mice 
given 200  l  Lm ( –L. major) antiserum on day 21 after infection (open 
circles). Parasite burdens (inset) were determined at 42 d after infection by 
limiting dilution assays as described previously (reference 3). Error bars 
represent the standard deviation of the mean of four determinations. 
This experiment is representative of three. 
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(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20041470/DC1).
 
IL-10 production during Leishmania infection
 
Cytokine production from lymph node T cells was analyzed
after infection of J
 
H
 
 mice with 
 
L. major
 
 in the presence or
absence of antibody. The administration of 
 
 
 
Lm-IgG re-
sulted in a significant increase in the production of IL-4 by
stimulated lymph node T cells (Fig. 3 A), but little to no de-
crease in the production of IFN-
 
 
 
 levels by these cells. Thus,
the presence of antibody to 
 
L. major
 
 correlates with an in-
crease in IL-4 production by parasite-specific T cells. How-
ever, the alteration in the production of these T cell cyto-
kines did not appear to be substantial enough to account for
the large differences in lesion formation in these mice. Con-
sequently, we examined a possible role for IL-10. We (3)
and others (4, 5) have previously shown that mice lacking
IL-10 were relatively resistant to leishmaniasis. We exam-
ined the production of IL-10 in the lesions of mice infected
with Leishmania. IL-10 mRNA and protein were measured
in infected feet 2 and 4 d, respectively, after the administra-
tion of 
 
 
 
Lm-IgG. J
 
H
 
 mice given a single dose of purified
 
 
 
Lm-IgG i.p. produced approximately twice as much IL-10
protein and mRNA in their lesions, relative to parallel
groups of mice infected at the same time, which did not re-
ceive IgG (Fig. 3 B).
To confirm a role for IL-10 in lesion progression, J
 
H
 
mice were infected with 
 
L. major
 
 and administered puri-
fied 
 
 
 
Lm-IgG along with a monoclonal antibody to the
IL-10 receptor (13). Infected J
 
H
 
 mice developed modest
lesions (Fig. 4, closed circles), whereas those administered
 
 
 
Lm-IgG developed large ulcerated lesions with high
numbers of parasites (Fig. 4, open circles). These mice had
to be killed due to excessive lesion progression. The ad-
ministration of a monoclonal antibody to the IL-10 recep-
tor completely prevented the exacerbation of disease caused
by 
 
 
 
Lm-IgG (Fig. 4, open triangles). In fact, lesions in
mice treated with 
 
 
 
Lm-IgG plus 
 
 
 
IL-10R were essentially
indistinguishable from uninfected feet by day 30 after in-
fection (unpublished data).
To determine whether irrelevant immune complexes
could have a similar effect on lesion progression, we immu-
nized the genetically resistant C57BL/6 mice with OVA in
IFA. 2 wk after a booster immunization, these mice had de-
veloped high titers of IgG antibody to OVA (unpublished
data). They were then infected with 
 
L. major
 
 suspended in a
solution of PBS containing 50 
 
 
 
g/ml OVA. Immunized
Figure 3. Cytokine production in mice administered anti–L. major 
antiserum. (A) Cytokine production by lymph node T cells from infected 
JH mice (white bars) was compared with JH mice administered 200  l  Lm 
( –L. major) antiserum on days 1, 7, and 14 after infection (black bars). 
Lymph nodes were removed on day 21 and stimulated with soluble leish-
mania antigen. Supernatants were harvested 72 h later and assayed for 
IFN-  and IL-4 by ELISA. (B) IL-10 production in lesions of JH mice. IL-10 
protein (left) and mRNA (right) were determined in two groups of JH mice 
infected with 2   105 L. major amastigotes. On day 21 of infection, one 
group was administered 600  g of purified  Lm-IgG i.p. IL-10 protein 
levels in the lesions of three infected mice were measured by ELISA 4 d 
after the administration of  Lm-IgG (left axis). RNA was isolated from 
footpad lesions on day 2 after IgG administration, and real-time PCR was 
performed to determine relative IL-10 mRNA (right axis). Levels represent 
the average from three infected mice, and mRNA was normalized to hypo-
xanthine phosphoribosyltransferase levels in a single infected foot.
Figure 4. IgG reconstitution of JH mice and the effect of  –IL-10R 
mAb. Three parallel groups of JH mice were infected with 2   105 L. major 
amastigotes. One group (open circles) was administered 600  g of puri-
fied  Lm-IgG i.p. on days 1, 8, and 15. Another group (gray triangles) was 
given the same dose of  Lm-IgG, along with  –IL-10R on days 0 (1 mg), 
7 (200  g), and 14 (200  g). The third group (closed circles) received no 
treatment. Lesion size was measured at semi-weekly intervals. Parasite 
burdens (inset) were determined by limiting dilution. Error bars represent 
the standard deviation of the mean. 
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mice making antibodies to OVA (Fig. 5, open circles), de-
veloped larger lesions with two logs more parasites (inset)
compared with sham immunized mice receiving IFA alone
and the same 
 
L. major
 
 infection (Fig. 5, closed circles).
 
In vitro studies on the mechanism of IgG-mediated 
immune enhancement
 
In vitro studies were performed to measure cytokine produc-
tion by macrophages infected in vitro with lesion-derived 
 
L.
major
 
 amastigotes (Fig. 6 A). To recreate the lesion environ-
ment, macrophages were cultivated with inflammatory low
molecular weight hyaluronic acid (LMW-HA) before infec-
tion as described previously (3). Uninfected macrophages cul-
tivated on LMW-HA produced relatively high levels of IL-
12 (Fig. 6 A, gray bars) and only modest levels of IL-10 (Fig.
6 A, black bars). The addition of lesion-derived amastigotes
to these cells caused a reciprocal change in cytokine produc-
tion. Infected macrophages produced low amounts of IL-12
and relatively high levels of IL-10 (Fig. 6 A) as described pre-
viously, using soluble immune complexes (11).
To determine the extent to which Leishmania infection
could influence APC function, macrophages were infected
with lesion-derived amastigotes, pulsed with OVA, and used
to present antigen to naive T cells from D011.10 mice, which
carry an OVA-specific transgenic TCR (14). Uninfected
macrophages cultivated with LMW-HA induced OVA-spe-
cific T cells to produce primarily IFN-
 
 
 
 when they were used
as APCs (Fig. 6 B, white bar). However, macrophages in-
fected with amastigotes preferentially induced the production
of IL-4 from T cells, with a marked decrease in IFN-
 
 
 
 (Fig. 6
B, black bar). Thus, infection of macrophages with Leishma-
nia amastigotes reverses their inflammatory cytokine profile,
and this can influence T cell cytokine production.
 
IgG antibodies in human VL
 
In vitro infection studies were performed to measure IL-10
production from human monocytes infected with Leishmania
chagasi amastigotes. For these studies, IgG-free axenically
grown L. chagasi amastigotes were used to infect normal hu-
man monocytes. Axenic amastigotes induced little to no de-
tectable IL-10 production from human monocytes (Fig. 7).
However, incubating these organisms in serum from a pa-
tient with VL induced the production of high levels of IL-10
from monocytes (Fig. 7). Parallel groups of axenic amasti-
gotes incubated in normal serum from uninfected volunteers
failed to induce IL-10 production from monocytes (Fig. 7).
Thus, serum from infected patients opsonizes amastigotes to
induce the production of IL-10 from infected monocytes.
To relate these experimental observations to human VL,
we examined a group of patients from Brazil who had bone
marrow aspirate-confirmed VL. We sought to correlate the
severity of VL with antibody levels and/or delayed-type hy-
persensitivity (DTH) responses. To do this, we examined a
total of 317 patients with VL. These patients were selected at
either the time of diagnosis or within  1 yr of treatment and
grouped together for this initial analysis. Of the total of 317
patients analyzed, 280 of them (88%) were antibody positive.
This is in stark contrast with patients with cutaneous leish-
maniasis, in which IgG antibody titers are typically low or
absent (15). Of these 280 antibody-positive patients, 252 of
Figure 5. The immunization of C57BL/6 mice with OVA. Lesion 
development in OVA-immunized mice (open circles) was compared with 
control mice given IFA alone (closed circles). Immunized mice were given 
25  g OVA in 500  L of IFA and boosted 2 wk later. Both groups of mice 
were infected with L. major resuspended in PBS containing 50  g/ml OVA. 
Parasite burdens (inset) were determined on day 34. Error bars represent 
the standard deviation of the mean.
Figure 6. In vitro cytokine production. (A) Lesion-derived L. major 
amastigotes were added to bone marrow–derived macrophages in the 
presence of inflammatory LMW-HA. Supernatants were harvested 24 h 
later and cytokines IL-12 (gray bars) and IL-10 (black bars) were measured 
by ELISA. (B) The production of cytokines, IFN-  and IL-4, from T cells was 
measured by ELISA 3 d after primary stimulation. OVA-specific TCR trans-
genic T cells were added to either uninfected (white bars) or L. major–
infected (black bars) macrophages cultivated with OVA and LMW-HA.JEM VOL. 201, March 7, 2005 751
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them (90%) were DTH negative. Conversely, of the 37 pa-
tients that were antibody negative, 31 of them (84%) were
DTH positive, P   0.0001 (Table in Fig. 8). The size of the
DTH response was also calculated in these patients. Anti-
body-negative individuals had a mean induration score of
9.53 mm, whereas antibody-positive subjects had essentially
no detectable DTH response, with an average induration of
only 1.08 mm (Fig. 8). Thus, there was a strong negative
correlation between antileishmanial IgG levels and DTH re-
sponses (P   0.007).
A subset of these patients who were analyzed at the time
of initial diagnosis were monitored at 6-mo intervals after
treatment. At the time of diagnosis, DTH responses were ab-
sent (Fig. 9, black bars) and antibody titers were high (Fig. 9,
white bars). After treatment, DTH responses progressively in-
creased over time, from  1 mm at the time of treatment to
 6 mm after 1 yr of successful treatment (Fig. 9). Conversely,
the mean antibody titers progressively declined over time
from a mean of 1.219 (  0.4753) to 0.246 (  0.222) post-
treatment (Fig. 9). Thus, in patients with VL, antibody levels
correlate with, and are predictive of, active disease. Disease
resolution after treatment parallels a decline in IgG and the
development of DTH responses to leishmanial antigens.
DISCUSSION
We examined a role for IgG immune complexes in leishma-
niasis, and conclude that IgG antibody not only fails to pro-
vide protection against this intracellular pathogen, but it can
actually contribute to disease progression. A previous obser-
vation had shown that IgG could aggravate Leishmania ama-
zonensis infections in mice (16), but did not identify a mech-
anism. We show the mechanism of this exacerbation is by
inducing activated macrophages to produce IL-10 rather
than IL-12. A role for IL-10 in leishmaniasis has been de-
scribed previously (3–5), but the production of this cytokine
has not been linked to the presence of IgG-containing im-
mune complexes, nor have the cells producing this cytokine
been definitively identified. Previous studies have identified
a role for regulatory T cells in sustaining murine cutaneous
leishmaniasis (17). These cells can produce IL-10, and regu-
latory T cells may be an important source of IL-10 during
disease progression. In the present work, we show that in-
fected macrophages can also produce IL-10 in response to
the appropriate stimulation. In this case, the stimulation is
host IgG, which combines with the parasite to form immune
complexes. IL-10 produced by macrophages can exert both
direct and indirect influences on disease progression. IL-10 is
a potent inhibitor of macrophage activation, providing a di-
rect way in which immune complexes can prevent parasite
Figure 7. Flow cytometry to detect intracellular IL-10. Human 
monocytes were infected with a 10:1 ratio of axenic amastigotes of 
L. chagasi. Before infection, some amastigotes were incubated at 4 C for 
15 min in 5% serum from either an uninfected volunteer (naive serum) or 
from a patient with visceral leishmaniasis (VL serum). Monocytes were 
incubated in Golgi stop for 2 h, fixed, and permeabilized and stained for 
intracellular IL-10 expression. Cells were gated on CD14 expression.
Figure 8. DTH and antibody responses in patients with visceral 
leishmaniasis (VL). Delayed-type hypersensitivity (DTH) reactions were 
measured in 317 bone marrow aspirate-confirmed VL patients. The mean 
induration size of the DTH response (in mm diameter) was measured at 48 
h. (inset table) The same VL patients were analyzed for antibody and DTH 
responses. Antibody levels were judged to be positive if they were  3 SD 
above a mean control titer. DTH responses  5 mm in diameter were judged 
to be positive. This figure designates a significant negative association 
between DTH and antibody responses. Pearson  2, df   1; P   0.0001.
Figure 9. DTH and Leishmania-specific antibody responses in VL 
patients after treatment. The mean diameter induration score of the 
DTH response, measured in mm, is shown by the black bars (left), and the 
mean antibody titers, expressed as OD reading, are shown by the white 
bars (right) as a function of time after treatment (abscissa).IMMUNE COMPLEXES INDUCE MACROPHAGE IL-10 PRODUCTION | Miles et al. 752
eradication, even in the presence of an ongoing immune re-
sponse. Immune complexes can also exert an indirect effect
by influencing APC cytokine production to bias T cell re-
sponses (Fig. 6 B). In lesions, macrophages (18) and dendritic
cells (19) are in close association with T cells, placing them
in a prime position to influence T cell cytokine production.
Immune complexes not only induce activated macrophages
to produce IL-10 (Fig. 6 A), but they also induce both mac-
rophages (9) and dendritic cells (20) to switch off their pro-
duction of IL-12.
The observations made in the murine model of leishma-
niasis were confirmed in patients with VL. We demonstrate
that high antileishmanial antibodies in human VL correlate
with peak parasitemia, and with negative DTH responses.
Successful treatment resulted in decreased antibody titres and
a restoration of DTH responses. Previous studies have iden-
tified immune complexes and rheumatoid factor to be high
in patients with VL (21, 22). Polyclonal B cell activation and
high antibody titers have been observed in canine as well as
human VL (23–25). In many ways, the infection of BALB/c
mice with L. major may be a better model for human VL
than for cutaneous leishmaniasis. These mice develop high
antibody titers, and the parasites frequently metastasize to
distant locations including the bone marrow, liver, and
spleen (26). Similar to human VL, BALB/c mice typically
succumb to infection with L. major. Finally, the DTH re-
sponse in these mice is smaller and more transient than in re-
sistant mice (27). Interestingly, 20 yr ago it was demon-
strated that the suppression of DTH responses in BALB/c
mice required the presence of B cells (28). Thus, some of the
observations made in the BALB/c model of infection with
L. major can likely be extended to human VL.
In summary, we have identified a novel form of anti-
body-dependent immune enhancement (ADE), where im-
mune complexes can influence cytokine production by
APCs and prevent the eradication of intracellular pathogens.
These observations may provide a general mechanism to ex-
plain ADE. The phenomenon of ADE has been observed in
Dengue hemorrhagic fever (29), where the presence of anti-
body causes a marked increase in viremia and viral patho-
genesis. Intracellular bacteria may also exploit IL-10 as a
mechanism to establish disease. Recent studies have associ-
ated the production of IL-10 from macrophages with the
progression of lepromatous leprosy (30). Finally, these obser-
vations may also strike a cautionary note pertaining to the
development of antibody-based vaccines against intracellular
pathogens (31, 32). The present studies would suggest that
antibody-mediated immune enhancement, resulting in IL-10
production from macrophages, should be considered as a
potential risk for some vaccination protocols.
MATERIALS AND METHODS
Patient population.  These studies were reviewed and approved by the
Universidad Federal do Rio Grande do Norte Ethical Committee (CEP-
UFRN 19/01), by the Brazilian National Ethical Committee of Research
(CONEP 4572), and by the IRB of the University of Maryland. Serum
was obtained from patients with parasitological confirmed cases of VL.
Antileishmanial antibodies were determined as described previously (33).
The cutoff for a positive titer was 3 SD above the mean value of control
sera, obtained from 30 uninfected unexposed individuals (34). Each sample
was analyzed in triplicate, and positive and negative controls were included
in all assays. The DTH response in these individuals was performed by in-
tradermal injection of 25  g of L. chagasi protein provided by the Infectious
Disease Research Institute as described previously (35). Montenegro skin
tests (DTH) were read after 48 h and scored as positive if the induration ex-
ceeded 5 mm in diameter. The means of antibody and DTH responses were
analyzed by Student’s t test for dependent groups. To examine the influence
of time and antibody on DTH response of patients with ongoing VL or in
the process of recovering, a factorial two-way analysis of variance was used.
Animal studies. These studies were reviewed and approved by the Uni-
versity of Maryland Institutional Animal Care and Use Committee. BALB/c
mice were purchased from the National Cancer Institute Charles River
Laboratories and from Taconic. JH mice were purchased from Taconic.
DO11.10 mice (14), which have a transgenic T cell receptor (TCR  ) for
OVA323-339, were purchased from The Jackson Laboratory and used as a
source of antigen-specific CD4  T cells.
Antibody production and administration.  Purified IgG against L. ma-
jor was obtained by passing serum from infected BALB/c mice through the
protein G column on a GradiFrac System (Amersham Biosciences). Purified
 –IL-10R monoclonal antibody (36) was provided by K. Moore (DNAX
Research Institute, Palo Alto, CA). IgG and  –IL-10R treatments were ad-
ministered by i.p. injections at designated times during the experiment.
Parasites, infection, and parasite quantitation. Lesion-derived L. ma-
jor amastigotes (WHO MHOM/IL/80/Friedlin) were isolated from infected
BALB/c mice as described previously (37). L. chagasi were obtained from a
Brazilian patient with VL. Axenic L. chagasi amastigotes were grown as de-
scribed previously (38). Mice were injected in the right hind footpad with
either 2   105 or 2   106 L. major amastigotes. Lesion size was determined
by using a caliper to measure the thickness of the infected footpad and sub-
tracting the thickness of the contralateral uninfected footpad as described
previously (3). Parasite burdens were determined by a serial dilution of single
cell suspensions made from excised lesions as described previously (3).
Cytokine production by infected macrophages.  Macrophages were
cultured overnight in 24-well plates at a density of 2   105 cells/well. Cells
were stimulated with 150  g/ml LMW-HA (Worthington) before the ad-
dition of a 10:1 ratio of lesion-derived (IgG positive) L. major amastigotes.
24 h after infection, supernatants were collected and IL-10 and IL-12 levels
were measured by ELISA as described previously (11). For opsonization of
amastigotes with IgG, axenically grown L. chagasi amastigotes were incu-
bated for 20 min at 4 C in nonimmune or immune serum from a patient
with parasite-confirmed VL.
IL-10 production by human monocytes infected with L. chagasi
amastigotes was measured by flow cytometry. Human monocytes were in-
fected with a 10:1 ratio of serum opsonized L. chagasi amastigotes in the
presence of 10 ng/ml LPS. After 15 min, monolayers were treated with
Golgi stop (BD Biosciences) for an additional 2 h. IL-10 was detected using
a PE rat  –mouse IL-10 monoclonal antibody (BD Biosciences).
IL-10 quantitation.  IL-10 protein and mRNA levels were measured in
infected feet after the administration of  Lm-IgG. JH mice were infected with
2   105 L. major amastigotes in the right hind footpad. 21 d after infection,
mice were given a single i.p. injection of 600  l  Lm-IgG. Control JH mice
remained untreated. mRNA levels were measured by real-time PCR. Total
RNA was extracted from the footpad lesions 48 h after treatment with
 -Leishmania IgG, using the RNAqueous-4PCR kit obtained from Ambion.
IL-10 levels were detected by real-time PCR. Real-time PCR was per-
formed using the ABI PRISM 7700 Sequence Detection System and SYBRJEM VOL. 201, March 7, 2005 753
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green core PCR reagents (Applied Biosystems). The murine IL-10 primer se-
quences used for this analysis were as follows: sense, 5 -CCACAAAG-
CAGCCTTGCA-3  and antisense, 5 -AGTAAGAGCAGGCAGCAT-
AGCA-3 . The hypoxanthine phosphoribosyltransferase primers used were
as follows: sense, 5 -GTTGGATACAGGCCAGACTTTGTTG-3  and an-
tisense, 5 -AGGGTAGGCTGGCCTATAGGCT-3 . IL-10 protein levels
were measured by ELISA. Lesions were homogenized in lysis buffer (15 mM
Tris-HCl, 0.5% Triton X-100, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2)
as described previously (39). Samples were incubated on ice for 30 min and
centrifuged at 850 g for 30 min. Supernatants were analyzed by ELISA.
T cell cytokine production.  CD4  T cells were prepared from the
spleens of DO11.10 mice by immunomagnetic negative depletion as de-
scribed previously (11). For T cell stimulation assays, 2   105 macrophages
were primed overnight with 100 U/ml rIFN-  (R&D Systems). Cells were
washed and stimulated with 150  g/ml LMW-HA in the presence of 150
 g/ml OVA (Worthington). Fresh amastigotes of L. major were isolated
from active lesions in BALB/c mice, washed, and added to some of the
macrophages at a 10:1 ratio. 5   105 CD4  T cells were added to each well
2 h later, in a total volume of 0.6 mL RPMI 1640 (Cellgro) supplemented
with 10% FCS, Hepes, penicillin/streptomycin, and  -mercaptoethanol.
Primary T cell cytokine measurements were made by ELISA at 72 h as
described previously (11).
Cytokine production by lymph node T cells was determined by
ELISA. In brief, mice were infected with L. major in the presence or ab-
sence of  Lm-IgG as described before. At day 21 after infection, lymph
nodes were removed, and unfractionated lymph node cells were stimulated
with 50  g/ml soluble leishmania antigen. Supernatants were collected 72 h
later, and IFN-  and IL-4 were measured by ELISA.
Immunization with OVA.  C57BL/6 mice were immunized against
OVA by giving 25  g OVA in 500  L of IFA (Difco Laboratories) by i.p.
injection. A control group was given IFA alone. 2 wk after the initial injec-
tion the mice received a “booster” dose of 25  g OVA in 500  L of IFA. 2
wk after receiving the second dose of OVA, some of the mice were bled to
confirm the presence of anti-OVA IgG. The rest of the littermates were in-
fected in the right hind footpad with 2   106 L. major amastigotes resus-
pended in PBS containing 50  g/ml OVA.
Online supplemental material. Disease progression in JH mice treated
with  Lm-IgG. Three groups of JH mice (five per group) were infected with
equal amounts of L. major amastigotes. At 20 d after infection, one group of
mice received 200  l of antisera from infected BALB/c mice and a second
group received 600  g purified IgG that was isolated from this antiserum.
The third (control) group received saline. Footpad swelling was measured
over the next 3 wk as described before. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20041470/DC1.
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